Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190031/S014

HER2 Dual ISH DNA Probe Cocktail

Ventana Medical Systems, Inc. · Decision date Dec 15, 2025

FDA DECISIONP190031/S014

What did the FDA approve?

FDA records P190031/S014 as a supplement to PMA P190031, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Dec 15, 2025.

FDA approval order statement

This 180-day supplement is to expand labeling of the HER2 Dual ISH DNA Probe Cocktail for use as a companion diagnostic to identify patients with HER2-positive, advanced or metastatic breast cancer who may be eligible for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with PERJETA (pertuzumab) as first-line treatment.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Dec 15, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P190031/S014
Regulatory pathway
PMA supplement
Product code
NYQ
Decision code
APPR
Decision date
Dec 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer.

Product code
NYQ
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190031/S014 received

    Application receipt date recorded by FDA.

  2. P190031/S014 · FDA decision

    Normal 180 Day Track

  3. P190031/S015 · Related supplement

    HER2 Dual ISH DNA Probe Cocktail

  4. P190031/S016 · Related supplement

    VENTANA HER2 Dual ISH DNA Probe Cocktail

Timeline entries are records held by MedtechLedger for P190031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190031

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc.PMA supplementMay 15, 2026FDA
Ventana Medical Systems, Inc.PMA supplementAug 25, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records